More than a participant in trials of cell and gene therapy: Hearing the voices of people living with neurodegenerative diseases

Lane, Emma L. ORCID: https://orcid.org/0000-0001-8800-3764, Isaacs, Lyndsey and Mathur, Soania 2022. More than a participant in trials of cell and gene therapy: Hearing the voices of people living with neurodegenerative diseases. Lane, Emma L., Drew, Cheney and Lelos, Mariah J., eds. International Review of Neurobiology, Vol. 166. Elsevier, pp. 281-312. (10.1016/bs.irn.2022.09.007)

Full text not available from this repository.

Abstract

With the advent of novel advanced therapy medicinal products (ATMPs) for neurodegenerative diseases, their pathway to clinical trials and the therapeutic landscape has highlighted some new challenges, many of which are outlined in other chapters of this volume. The practical considerations of all these aspects from basic research and animal models through to clinical trials and eventual clinical implementation are significant. By and large, the major voices surrounding these challenges are the scientists and clinical teams who both develop the interventions and design and deliver the clinical trials to test these novel ATMPs. Their expertise is of course essential, but there is a key voice that can add considerable benefit to the pipeline, that of the lived experience of the disease being treated and the new intervention being considered. While still in their relative infancy in neurodegenerative disease, some ATMPs are already in clinical application in other disease areas, mainly cancer and inherited disorders. This more advanced status has raised some interesting questions about the role of the patient voice across all aspects of the therapeutic research and clinical delivery pipeline. This chapter highlights what has been learnt from the patient voice in their understanding and perspectives of ATMPs and in their experiences of clinical trials in neurodegenerative diseases to date. We discuss when, and how, including people living with neurodegenerative disease is of value in the development and implementation of ATMPs and the questions this collaborative effort can allow us to answer.

Item Type:	Book Section
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Elsevier
ISSN:	0074-7742
Last Modified:	08 Jul 2024 14:32
URI:	https://orca.cardiff.ac.uk/id/eprint/154543

Actions (repository staff only)

Edit Item